Navigation Links
Rhythmia Medical Highlights Studies to be Presented at Heart Rhythm Society 2011 Annual Scientific Session

BURLINGTON, Mass., April 28, 2011 /PRNewswire/ -- Rhythmia Medical Inc., announced today that key results from its ongoing pre-clinical and clinical studies will be presented at the 2011 Annual Scientific Session of the Heart Rhythm Society in San Francisco, CA. The results will highlight the performance of Rhythmia Medical's mapping system, a technological breakthrough that can significantly improve cardiac ablation procedures by generating high resolution electroanatomical maps faster, simpler and more accurately.

The following presentations are planned:

  • "New System for Rapid, High-Resolution Automated Mapping in Patients with Macroreentrant Atrial Tachycardia/Flutter"
    Dr. Hiroshi Nakagawa, Director of the Clinical Catheter Ablation Program and Translational Electrophysiology at the University of Oklahoma , will present the initial results from the first in man clinical trial using the system for mapping macroreentrant atrial tachycardia and atrial flutter in the session "New Technologies Facilitating Successful Catheter Ablation" on Thursday, May 5, 1:30 - 3:00 p.m. in Moscone West room 2002.
    Dr. Nakagawa will present results from initial investigational studies performed with the cooperation of Professor Josef Kautzner and his team at the Institute for Clinical and Experimental Medicine (IKEM) in Prague.  The study included patients with Atrial Fibrillation, Atrial Tachycardia and Atrial Flutter.

  • "New System for Rapid, High-Resolution Automated Electroanatomical Mapping: Evaluation in a Canine Atrial Incision Model"
    Dr. Hiroshi Nakagawa will present the poster for this pre-clinical study in canines demonstrating the potential of the system to rapidly identify areas of conduction block in the right atrium after linear lesions are created surgically and by ablation. This poster session will be featured on Thursday, May 5, 9:00 AM -12:00 PM. The presentation will show the resolution and performance of the Rhythmia system in this complex experimental model.Cardiac arrhythmia affects more than 7.5 million people in the United States and Europe, and is a life- threatening condition that can lead to stroke or heart failure. Catheter ablation procedures, currently performed at a rate of over 500,000 per year, represent a $2 billion market with one of the fastest growth rates in medical devices.

    The new research provides new insight into the capability of the Rhythmia Medical's mapping system to support catheter ablation procedures by providing a highly accurate electroanatomical map within minutes. "Mapping accuracy is critically important to make sure we can correctly identify the optimal ablation target to minimize unnecessary ablation and avoid repeat procedures. The ability to quickly generate such high resolution maps with minimal operator involvement during mapping will enhance the way Electrophysiologists perform catheter ablation in the future," said Dr. Warren M. (Sonny) Jackman of the University of Oklahoma who participated in the studies.

    Rhythmia Medical's mapping system is an investigational device and is not available for sale in the United States.

    About Rhythmia MedicalFounded in 2004, Rhythmia Medical, Inc. is developing a next generation Mapping, Visualization and Navigation system for the treatment of cardiac arrhythmias. The company recently began human clinical testing outside the US and is working with several of the leading clinicians in this field around the world. The Burlington, Massachusetts-based venture-backed company has raised $19 million of financing. Additional information can be found at


  • SOURCE Rhythmia Medical, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center First in the United States to Utilize Newly FDA-Cleared CARTO(R) 3 Navigation System
    2. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
    3. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    4. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
    5. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2011
    6. Southern Home Medical Equipment Reports First Quarter 2011 Results in Revenues and Profits
    7. China Medical Technologies to Announce Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2011 on June 2, 2011
    8. Dehaier Medical to Report First Quarter 2011 Financial Results on May 4
    9. Rochester Medical Announces Second Quarter 2011 Earnings Conference Call Thursday, May 5, 2011
    10. LATEST Medical Introduces New Kind of Patient Information Web Site -
    11. Neusoft to Invest in Israeli Medical Solutions Company for Accelerating Expansion in Global Healthcare Service Market
    Post Your Comments:
    (Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
    (Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
    (Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
    (Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
    (Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
    (Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
    (Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
    Breaking Medicine News(10 mins):